ReviewExpert review of anticancer therapy2009
Targeting the Met signaling pathway in renal cancer.
Review in Expert review of anticancer therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- A Phase I Trial of the MET/OncoTargets and therapy · 2021Trial
- PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.International journal of molecular sciences · 2023Review
- Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.Frontiers in oncology · 2022Review
- Review
- Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks.Scientific reports · 2021Article
- Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.International urology and nephrology · 2019Review
- A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.Kidney cancer (Clifton, Va.) · 2019Review
- Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1.Oncogenesis · 2019Article
- Article
- Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice.Kidney cancer (Clifton, Va.) · 2017Review
- Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Scientific reports · 2017Article
- In silico identification of potential key regulatory factors in smoking-induced lung cancer.BMC medical genomics · 2017Article
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.Clinical pharmacokinetics · 2017Review
- Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.American journal of translational research · 2017Article
- C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Oncotarget · 2016Article
- Bone Metastasis from Renal Cell Carcinoma.International journal of molecular sciences · 2016Review
- Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.Drug design, development and therapy · 2016Review
- Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.Cancer biology & therapy · 2015Article
- c-Met as a Target for Personalized Therapy.Translational oncogenomics · 2015Review
- Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.Molecular imaging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for 3% of all adult malignancies and its incidence has significantly increased over the last 20 years. RCC claims 13,000 lives annually in the USA and more than 100,000 worldwide. A better understanding of the molecular basis of RCC has facilitated the development of novel and more selective therapeutic approaches. An important role in RCC oncogenesis is played by the receptor for HGF, Met, which has attracted considerable attention, more recently as a molecular target for cancer therapy, and several drugs selectively targeting this pathway are now in clinical trials. This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.